A novel series of 2-pyridyl-containing compounds as lysophosphatidic acid receptor antagonists: Development of a nonhydrolyzable LPA3 receptor-selective antagonist

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 15, 2004, Pages 4069-4074

  Heasley, Brian H ^a   Jarosz, Renata ^b   Carter, Karen M ^a   Van, S Jenny ^a   Lynch, Kevin R ^b   Macdonald, Timothy L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Lysophosphatidic acid receptor antagonist

Indexed keywords

LYSOPHOSPHATIDIC ACID; PYRIDINE DERIVATIVE;

ADDITION REACTION; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; MASS SPECTROMETRY; PROTON NUCLEAR MAGNETIC RESONANCE;

ANIMALS; FIBROBLASTS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PYRIDINES; RECEPTORS, LYSOPHOSPHATIDIC ACID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3042640422     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.05.023     Document Type: Article

References (24)

1. Tigyi G., Parrill A.L. Prog. Lipid Res. 42:2003;498-526
2. Mills G.B., Moolenaar W.H. Nat. Rev. Cancer. 3:2003;582-591
3. Sciorra V.A., Morris A.J. Biochim. Biophys. Acta. 1582:2002;45-51
4. Brindley D.N., Waggoner D.W. J. Biol. Chem. 273:1998;24281-24284
5. Hooks S.B., Ragan S.P., Lynch K.R. FEBS Lett. 427:1998;188-192
6. Dillon D.A., Chen X., Zeimetz G.M. J. Biol. Chem. 272:1997;10361-10366
7. Xu J., Love L.M., Singh I., Zhang Q.-X., Dewald J., Wang D.-A., Fischer D.J., Tigyi G., Berthiaume L.G., Waggoner D.W., Brindley D.N. J. Biol. Chem. 275:2000;27520-27530
8. Hooks S.B., Santos W.L., Im D.-S., Heise C.E., Macdonald T.L., Lynch K.R. J. Biol. Chem. 276:2001;4611-4621
9. Alderton F., Darroch P., Sambi B., McKie A., Ahmed I.S., Pyne N., Pyne S. J. Biol. Chem. 276:2001;13452-13460
10. Quian L., Xu Y., Hasegawa Y., Aoki J., Mills G.B., Prestwich G.D. J. Med. Chem. 46:2003;5575-5578
11. Heasley B.H., Jarosz R., Lynch K.R., Macdonald T.L. Bioorg. Med. Chem. Lett. 14:2004;2735-2740
12. Haudrechy A., Chassaing C., Riche C., Langlois Y. Tetrahedron. 56:2000;3181-3187
13. Kuhler T.C., Fryklund J., Bergman N.-A., Weilitz J., Lee A., Larsson H. J. Med. Chem. 38:1995;4906-4916
14. Reetz M.T., Drewes M.W., Schmitz A. Angew. Chem., Int. Ed. Engl. 26:1987;1141-1143
15. Blackburn G.M., Parratt M.J. J. Chem. Soc., Chem. Commun. 1982;1270-1271
16. 6P: C, 65.76; H, 8.53; N, 4.65. Found: C, 64.63; H, 8.53; N, 4.58. (S)-Phosphoric acid mono-{2-octadec-9-enoylamino-3-[4-(pyridin-3- ylmethoxy)-phenyl]-propyl} ester (7b): this product had spectroscopic properties identical to its enantiomer
17. Im D.S., Heise C.E., Harding M.A., George S.R., O'Dowd B.F., Theodorescu D., Lynch K.R. Mol. Pharm. 57:2000;753-759
18. 3: 10 μM) was collided with antagonists at concentrations ranging from 0.1 to 30, 000 nM. Points are in triplicate and are representative of at least two experiments
19. Olbe L., Carlsson E., Lindberg P. Nature Rev. Drug Disc. 2:2003;132-139
20. Brown H.C., Mihm X.R. J. Am. Chem. Soc. 77:1955;1723-1726
21. Kaljurand I., Rodima T., Leito I., Koppel I.A., Schwesinger R. J. Org. Chem. 65:2000;6202-6208
22. Nieschalk J., Batsanov A.S., O'Hagan D., Howard J.A.K. Tetrahedron. 52:1996;165-176
23. Swierczek K., Pandey A.S., Peters J.W., Hengge A.C. J. Med. Chem. 46:2003;3703-3708
24. Santos W.L., Heasley B.H., Jarosz R., Carter K.M., Lynch K.R., Macdonald T.L. Bioorg. Med. Chem. Lett. 14:2004;3473-3476